Mend Therapeutics' Pipeline

MEND aims to create novel, first-in-class therapeutics and devices for the treatment of diabetic complications. Our first therapeutics MT-003, currently in Preclinical Development, is for the treatment of chronic diabetic foot wounds.

Our Solutions >>  Our Pipeline >>  MT-003  >> Future Vision >> Drug Development

We will work with academic, pharmaceutical, and other medical reseach partners to support basic medical research and help identify additional promising drug candidates and devices for the treatment of diabetic complications.